A
A Sanchez-Hernandez
Publications - 10
Citations - 220
A Sanchez-Hernandez is an academic researcher. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 1, co-authored 1 publications receiving 151 citations.
Papers
More filters
Journal ArticleDOI
Compliance, satisfaction, and quality of life of patients with colorectal cancer receiving home chemotherapy or outpatient treatment: a randomised controlled trial
Josep M. Borràs,A Sanchez-Hernandez,Matilde Navarro,M. E. Martínez,E Mendez,J L L Ponton,J. A. Espinàs,J R Germa +7 more
TL;DR: Home chemotherapy seems an acceptable and safe alternative to hospital treatment for patients with colorectal cancer that may improve compliance and satisfaction with treatment.
Journal ArticleDOI
COAST: An Open-Label, Phase II, Multidrug Platform Study of Durvalumab Alone or in Combination With Oleclumab or Monalizumab in Patients With Unresectable, Stage III Non–Small-Cell Lung Cancer
Roy S. Herbst,Margarita Majem,Fabrice Barlesi,Enric Carcereny,Quincy Chu,Isabelle Monnet,A Sanchez-Hernandez,Shaker R. Dakhil,D. Ross Camidge,Leanne Winzer,Yee Soo-Hoo,Zachary A. Cooper,Rajesh Kumar,John Bothos,Charu C. Aggarwal,Alex Martinez-Marti +15 more
TL;DR: Both combinations increased ORR and prolonged PFS versus durvalumab alone and safety was similar across arms with no new or significant safety signals identified with either combination, which support their further evaluation in a phase III trial.
Journal ArticleDOI
Clinical impact of delays in the management of lung cancer patients in the last decade: systematic review
M. Guirado,E. Fernández Martín,Alberto Fernández-Villar,Arturo Navarro Martín,A Sanchez-Hernandez +4 more
TL;DR: This article conducted a systematic search of observational studies (2010-2020) including adult patients diagnosed with lung cancer and reporting healthcare timelines and their clinical consequences; they included 38 articles containing data on waiting times and prognosis; only 31 articles linked this forecast to a specific waiting time.
Journal ArticleDOI
A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial.
Miguel Angel Climent,Albert Font,Ignacio Duran,Javier Puente,María José Méndez-Vidal,María Isabel Sáez,C. Santander Lobera,Jóse Ángel Arranz Arija,A. González-del-Alba,A Sanchez-Hernandez,María José Juan Fita,Emilio Esteban,Teresa Alonso-Gordoa,B. Mellado Gonzalez,Pablo Maroto,Martín Lázaro-Quintela,Javier Cassinello Espinosa,Begoña Perez-Valderrama,Carmen Garcías,Daniel Castellano +19 more
TL;DR: In this article , the efficacy and safety of maintaining or withdrawing abiraterone acetate plus prednisone (AAP) in patients with metastatic castration-resistant prostate cancer were compared.
Journal ArticleDOI
Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden
Mariano Provencio,Ana Ortega,Juan Coves Sarto,Virginia Calvo,R. Marse-Fabregat,Manuel Domine,M. Guirado,Enric Carcereny,Natalia Fernandez,Ruth Alvarez,R. Blanco,Luis León-Mateos,J.M. Sánchez-Torres,Ivana Sullivan,Manuel Cobo,A Sanchez-Hernandez,Bartomeu Massuti,Belén Sierra-Rodero,Cristina Martinez-Toledo,Roberto Serna-Blasco,Atocha Romero,Alberto Cruz-Bermúdez +21 more
TL;DR: In this paper , the authors evaluated the clinical benefits and safety of atezolizumab plus bevacizumaab for treatment of patients with metastatic non-small cell lung cancer (NSCLC) with high tumor mutation burden.